Health Dictionary
Reliable, easy-to-read patient information on common medical conditions — written in plain language, free of jargon, and grounded in current evidence. Browse the most frequent diagnoses, understand what they mean for everyday life, and learn which steps and questions help you have a focused conversation with your doctor.
Parkinsonism differential diagnosis
Introduction
Differentiating Parkinsonism from other Diseases
Differentiating Parkinsonism from other Diseases
If PD has been excluded, the differential diagnosis or list of potential causes for this syndrome includes:
- AIDS can sometimes lead to the symptoms of Parkinson’s disease, due to commonly causing dopaminergic dysfunction.[1]
- Corticobasal degeneration[2]
- Creutzfeldt-Jakob disease[3]
- Diffuse Lewy body disease[2]
- Drug-induced parkinsonism (due to drugs such as antipsychotics, metoclopramide, MPTP[4])[2]
- Encephalitis lethargica[2]
- Multiple system atrophy[5]
- Pantothenate kinase-associated neurodegeneration (Hallervorden-Spatz syndrome)[6]
- Progressive supranuclear palsy[2]
- Toxicity due to substances such as carbon monoxide,[7] carbon disulfide,[7] manganese,[7]paraquat,[8] hexane,rotenone, and toluene.
- Vascular parkinsonism[9]
- Wilson’s disease is a genetic disorder in which there is an abnormal accumulation of copper. The excess copper can lead to the formation of a copper-dopamine complex, which leads to the oxidation of dopamine to aminochrome.[10]
- Paraneoplastic syndrome. Neurological symptoms caused by antibodies associated with various cancers.
References
References
- ↑ Tse W, Cersosimo MG, Gracies JM; et al. (2004). “Movement disorders and AIDS: a review”. Parkinsonism Relat. Disord. 10 (6): 323–34. doi:10.1016/j.parkreldis.2004.03.001. PMID 15261874.
- ↑ 2.0 2.1 2.2 2.3 2.4 Invalid
<ref>tag; no text was provided for refs namedAminoff_2005 - ↑ Maltête D, Guyant-Maréchal L, Mihout B, Hannequin D (2006). “Movement disorders and Creutzfeldt-Jakob disease: a review”. Parkinsonism Relat. Disord. 12 (2): 65–71. doi:10.1016/j.parkreldis.2005.10.004. PMID 16364674.
- ↑ Watanabe Y, Himeda T, Araki T (2005). “Mechanisms of MPTP toxicity and their implications for therapy of Parkinson’s disease” (PDF). Med. Sci. Monit. 11 (1): RA17–23. PMID 15614202.
- ↑ Wenning GK, Geser F (2003). “Multiple system atrophy”. Rev. Neurol. (Paris). 159 (5 Pt 2): 3S31–8. PMID 12773886.
- ↑ Uc EY, Rodnitzky RL (2003). “Childhood dystonia”. Seminars in pediatric neurology. 10 (1): 52–61. doi:10.1016/S1071-9091(02)00010-4. PMID 12785748.
- ↑ 7.0 7.1 7.2 DeLong MR, Juncos JL (2004). Parkinson’s Disease and Other Movement Disorders. In: Harrison’s Principles of Internal Medicine (16th ed. ed.). McGraw-Hill Professional. pp. p. 2414. ISBN 0-07-140235-7.
- ↑ Dinis-Oliveira RJ, Remião F, Carmo H; et al. (2006). “Paraquat exposure as an etiological factor of Parkinson’s disease”. Neurotoxicology. 27 (6): 1110–22. doi:10.1016/j.neuro.2006.05.012. PMID 16815551.
- ↑ Thanvi B, Lo N, Robinson T (2005). “Vascular Parkinsonism–an important cause of parkinsonism in older people” (PDF). Age and ageing. 34 (2): 114–9. doi:10.1093/ageing/afi025. PMID 15713855.
- ↑ CzÅ‚onkowska A, Tarnacka B, Möller JC; et al. (2007). “Unified Wilson’s Disease Rating Scale – a proposal for the neurological scoring of Wilson’s disease patients”. Neurol. Neurochir. Pol. 41 (1): 1–12. PMID 17330175.
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]